Pharmacological treatment for attention deficit hyperactivity disorder: functional outcomes in children and adolescents from non-Western countries

Article Page

Abstract

Objective: Functional outcomes were measured over a 12-month period in children and adolescents with attention deficit hyperactivity disorder (ADHD) after they received monotherapy. Design: Prospective, observational, noninterventional study.

Setting: Conducted in six non-Western countries.

Participants: Outpatients 6 to 17 years of age with a verified diagnosis of ADHD in accordance with the Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR), together with their physicians, decided to initiate or switch treatment for ADHD. Patients were prescribed pharmacological monotherapy: methylphenidate (n=221), nootropic agents (n=91), or atomoxetine (n=234).

Measurements: Patients were followed for changes in their functional status and quality of life, which were assessed with the Child Health and Illness Profile–Child Edition (CHIPCE) Achievement domain.

Results: At the end of the study, a mean improvement on the CHIP-CE Achievement domain score was observed for all countries and therapies except in Taiwan, where patients received atomoxetine, and in Lebanon, where patients received methylphenidate. No patient experienced a serious adverse event during the study. Four patients discontinued due to a treatment-emergent adverse event.

Conclusion: After 12 months of treatment, clinical and functional outcomes were improved in children and adolescents from non-Western countries who initiated and remained on their prescribed pharmacological monotherapy.

Keywords: atomoxetine, attention deficit hyperactivity disorder, adolescent, child, adverse drug events, treatment outcome, nootropic agents, central nervous system stimulants

Citation: Altin M, El-Shafei AA, Yu M, Desaiah D, Treuer T, Zavadenko NN, Gao HY. Pharmacological treatment for attention deficit hyperactivity disorder: functional outcomes in children and adolescents. Drugs in Context 2013;212260. doi: 10.7573/dic.212260

Provenance: Submitted; externally peer reviewed

Dates: Submitted: 8 May 2013
; Accepted, subject to peer review: 10 May 2013
; Published: 13 September 2013

Copyright: © 2013 Altin M, El-Shafei AA, Yu M, Desaiah D, Treuer T, Zavadenko NN, Gao HY. This is an open-access article distributed under the terms of the Creative Commons Attribution License Deed CC BY NC ND 3.0 which allows anyone to copy, distribute and transmit the article provided it is properly attributed in the manner specified below. No other uses without permission.

Correct attribution: Copyright © 2013 Altin M, El-Shafei AA, Yu M, Desaiah D, Treuer T, Zavadenko NN, Gao HY. http://dx.doi.org/10.7573/dic.212260. Published by Drugs in Context under Creative Commons Attribution License Deed CC BY NC ND 3.0.

Correspondence: Murat Altin, MD; Lilly Turkey; Lilly İlaç Tic. Ltd. Şti.Kuşbakişi Caddesi, Rainbow Plaza No:4 Kat:3,34662; Altunizade, Istanbul, Turkey

Email: altin_murat@lilly.com

Download free full text PDF